- Home
- RCKT vs BEAM Comparison
RCKT vs BEAM Comparison
Compare RCKT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- BEAM
- Stock Information
- Founded
- RCKT 1999
- BEAM 2017
- Country
- RCKT United States
- BEAM United States
- Employees
- RCKT N/A
- BEAM N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCKT Health Care
- BEAM Health Care
- Exchange
- RCKT Nasdaq
- BEAM Nasdaq
- Market Cap
- RCKT 264.0M
- BEAM 1.9B
- IPO Year
- RCKT N/A
- BEAM 2020
- Fundamental
- Price
- RCKT $2.81
- BEAM $19.45
- Analyst Decision
- RCKT Buy
- BEAM Strong Buy
- Analyst Count
- RCKT 13
- BEAM 11
- Target Price
- RCKT $18.50
- BEAM $48.90
- AVG Volume (30 Days)
- RCKT 3.6M
- BEAM 2.4M
- Earning Date
- RCKT 08-04-2025
- BEAM 08-05-2025
- Dividend Yield
- RCKT N/A
- BEAM N/A
- EPS Growth
- RCKT N/A
- BEAM N/A
- EPS
- RCKT N/A
- BEAM N/A
- Revenue
- RCKT N/A
- BEAM $63,578,000.00
- Revenue This Year
- RCKT N/A
- BEAM N/A
- Revenue Next Year
- RCKT N/A
- BEAM $17.18
- P/E Ratio
- RCKT N/A
- BEAM N/A
- Revenue Growth
- RCKT N/A
- BEAM N/A
- 52 Week Low
- RCKT $2.19
- BEAM $13.53
- 52 Week High
- RCKT $26.98
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- RCKT 41.85
- BEAM 63.94
- Support Level
- RCKT $2.76
- BEAM $20.75
- Resistance Level
- RCKT $3.24
- BEAM $22.51
- Average True Range (ATR)
- RCKT 0.19
- BEAM 1.18
- MACD
- RCKT 0.13
- BEAM 0.35
- Stochastic Oscillator
- RCKT 49.10
- BEAM 74.58
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.